Sofia: The figures arrive every month with bureaucratic regularity, and every month they tell a worse story. On 29 May the European Centre for Disease Prevention and Control published its latest measles and rubella monitoring report, covering April, and the picture is of a disease that the continent once had on the run regaining ground. In the preceding month thirty countries across the EU and the wider European Economic Area reported data, and case numbers rose again, with active outbreaks flagged in Bulgaria, France and Portugal.
Measles is not a mild illness, and its resurgence is not bad luck. It is among the most contagious infections known, capable of spreading to nine in ten susceptible people exposed to it, which is why public-health doctrine sets an unusually high bar for control: roughly 95 percent of a population must be immunised with two doses of the vaccine to deny the virus the chain of unprotected hosts it needs. Across much of Europe coverage has slipped below that threshold, and the gaps are not evenly spread. They cluster in particular communities, regions and age cohorts, leaving pockets where a single imported case can seed a sustained outbreak.
The drivers are familiar and stubborn. Routine childhood immunisation was disrupted during the pandemic years, leaving a cohort of children who missed scheduled doses and were never fully caught up. Vaccine hesitancy, amplified online, has eaten into confidence in some areas. And the practical friction of reaching marginalised or mobile populations means coverage statistics that look adequate nationally can conceal dangerous shortfalls locally. The agency’s surveillance work, which combines formal case reporting with epidemic-intelligence monitoring, is designed precisely to spot those local flare-ups before they merge into something larger.
The centre has paired the grim monthly numbers with a push for transparency. It has launched a vaccination-coverage dashboard that displays, in one place, how countries are performing not only on measles and rubella but on hepatitis B and human papillomavirus immunisation as well, drawing on a parallel review of HPV programmes. The logic is that sunlight aids accountability: a health ministry able to see exactly where its coverage trails its neighbours, and to have that visible to others, has a sharper incentive to act. The dashboard turns a diffuse, slow-moving problem into something measurable and comparable.
What the data cannot do is administer vaccines. The European Centre advises and monitors; immunisation policy and delivery remain national competences, and the unevenness of Europe’s response reflects that. Some governments have responded to rising cases with catch-up campaigns and school-entry checks; others have been slower. The virus exploits the seams between systems, and travellers carry it across borders that the pathogen, unlike the bureaucracy, does not recognise.
The arithmetic of measles is unforgiving precisely because it is so well understood. Unlike many threats the agency tracks, this one has a cheap, safe, decades-old solution, and a clear target for how widely it must be used. The recurring monthly reports are, in a sense, a measure of distance from a goal that is entirely achievable. That a preventable disease is climbing again on a wealthy continent is less a scientific failure than a collective one, and the figures will keep arriving until enough children are protected to make them dull again.
